Most Read Articles
Jairia Dela Cruz, 3 days ago
Metabolic and bariatric surgery (MBS) leads to large and sustained reductions in, and even reversal of, multiple risk factors for future joint disease in adolescents with severe obesity and musculoskeletal pain, according to data from the Teen Longitudinal Assessment of Bariatric Surgery study.
Pearl Toh, 31 Dec 2019
Adding the neuraminidase inhibitor oseltamivir to usual care speeds up recovery from influenza-like illness by a day compared with usual care alone, with even greater benefits seen in older, sicker patients with comorbidities, according to the ALIC4E study.
23 Dec 2019
At a Menarini-sponsored symposium held during the Asian Pacific Society Congress, renowned cardiologist Prof John Camm provided the latest evidence for chronic stable angina with or without concomitant diseases, with a special focus on the antianginal agent ranolazine and combination therapies. The event was chaired and moderated by Dr Dante Morales from the University of the Philippines College of Medicine.
Pearl Toh, 6 days ago
Obeticholic acid significantly improves fibrosis and disease activity in patients with nonalcoholic steatohepatitis (NASH), a chronic liver disease currently with no approved therapy, according to an interim analysis of the landmark REGENERATE* study.

Adherence, persistence to oral anticoagulants in first year of treatment suboptimal

08 Nov 2019

Adherence and persistence to oral anticoagulants (OACs) the first year of treatment appear to be relatively low across drugs, a study has found.

Researchers looked at time trends at individual and system levels, as well as the risk factors for and associations between adherence and persistence, using data from the UK primary care EHR (The Health Information Network 2011–2016).

The analysis included 36,652 individuals with incident atrial fibrillation, cardiovascular comorbidities (median CHA2DS2VASc [Congestive heart failure, Hypertension, Age≥75 years, Diabetes mellitus, Stroke, Vascular disease, Age 65–74 years, Sex category], 3) and polypharmacy (median number of drugs, 6).

Adherence rates at 1 year after treatment initiation were 55.2 percent (95 percent confidence interval [CI], 54.6–55.7) for all OACs, 51.2 percent (95 percent CI, 50.6–51.8) for vitamin K antagonist (VKA), 66.5 percent (95 percent CI, 63.7–69.2) for dabigatran, 63.1 percent (95 percent CI, 61.8–64.4) for rivaroxaban and 64.7 percent (95 percent CI, 63.2–66.1) for apixaban.

One-year persistence rates were 65.9 percent (95 percent CI, 65.4–66.5) for all OACs, 63.4 percent (95 percent CI, 62.8–64.0) for VKA, 61.4 percent (95 percent CI, 58.3–64.2) for dabigatran, 72.3 percent (95 percent CI, 70.9–73.7) for rivaroxaban and 78.7 percent (95 percent CI, 77.1–80.1) for apixaban.

Nonadherence and nonpersistence increased over time at individual and system levels. Increasing comorbidity was associated with a lower likelihood of nonadherence and nonpersistence across all OACs.

Overall, the rate of ‘primary nonadherence’ (stopping after first prescription) was 3.5 percent, ‘nonadherent nonpersistence’ 26.5 percent and ‘persistent adherence’ 40.2 percent. These rates varied across OACs.

The present data may help to better understand the determinants of adherence and persistence, and to design and target interventions to improve adherence and persistence together across drugs, according to the researchers.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Doctor - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Jairia Dela Cruz, 3 days ago
Metabolic and bariatric surgery (MBS) leads to large and sustained reductions in, and even reversal of, multiple risk factors for future joint disease in adolescents with severe obesity and musculoskeletal pain, according to data from the Teen Longitudinal Assessment of Bariatric Surgery study.
Pearl Toh, 31 Dec 2019
Adding the neuraminidase inhibitor oseltamivir to usual care speeds up recovery from influenza-like illness by a day compared with usual care alone, with even greater benefits seen in older, sicker patients with comorbidities, according to the ALIC4E study.
23 Dec 2019
At a Menarini-sponsored symposium held during the Asian Pacific Society Congress, renowned cardiologist Prof John Camm provided the latest evidence for chronic stable angina with or without concomitant diseases, with a special focus on the antianginal agent ranolazine and combination therapies. The event was chaired and moderated by Dr Dante Morales from the University of the Philippines College of Medicine.
Pearl Toh, 6 days ago
Obeticholic acid significantly improves fibrosis and disease activity in patients with nonalcoholic steatohepatitis (NASH), a chronic liver disease currently with no approved therapy, according to an interim analysis of the landmark REGENERATE* study.